(VIANEWS) – PANORO ENERGY (PEN.OL), KBC (KBC.BR), SPBK1 RINGERIKE (RING.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. PANORO ENERGY (PEN.OL)
84.8% sales growth and 21.81% return on equity
Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is based in London, the United Kingdom.
Earnings Per Share
As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr3.98.
PE Ratio
PANORO ENERGY has a trailing twelve months price to earnings ratio of 7.94. Meaning, the purchaser of the share is investing kr7.94 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.81%.
Volume
Today’s last reported volume for PANORO ENERGY is 216185 which is 47.03% below its average volume of 408184.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Sep 12, 2023, the estimated forward annual dividend rate is 0.87 and the estimated forward annual dividend yield is 2.81%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PANORO ENERGY’s EBITDA is 17.89.
Sales Growth
PANORO ENERGY’s sales growth is negative 32.7% for the ongoing quarter and 84.8% for the next.
More news about PANORO ENERGY.
2. KBC (KBC.BR)
31.5% sales growth and 15.09% return on equity
KBC Group NV, together with its subsidiaries, provides integrated bank-insurance services primarily for retail, private banking, small and medium sized enterprises, and mid-cap clients. The company offers demand deposits and savings accounts; home and mortgage loans; consumer finance and SME funding services; credit, investment fund and asset management, and life and non-life insurance; and cash management, payments, trade finance, lease, money market, capital market products, and stockbroking services. It also provides digital and mobile banking services. The company was formerly known as KBC Bank and Insurance Holding Company NV and changed its name to KBC Group NV in March 2005. KBC Group NV was incorporated in 1935 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, KBC has a trailing twelve months EPS of €7.68.
PE Ratio
KBC has a trailing twelve months price to earnings ratio of 7.72. Meaning, the purchaser of the share is investing €7.72 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.09%.
Volume
Today’s last reported volume for KBC is 88162 which is 83.03% below its average volume of 519779.
More news about KBC.
3. SPBK1 RINGERIKE (RING.OL)
21.7% sales growth and 10.56% return on equity
SpareBank 1 Ringerike Hadeland provides various banking products and services to private and corporate customers in Norway. The company offers saving, current, deposit, and currency accounts; vehicle, house and travel, and animal insurance products, as well as life, child, disability, critical illness, accident, health, and business and personal insurance products; mobile and online banking services; and debit and credit cards. It also provides mortgages; car, boat, and other vehicles; consumer and other loans; and bank guarantees, corporate and construction loans, liquidity loans with a government guarantee, and operating credit for agriculture, as well as factoring, leasing, and overdraft services. In addition, the company offers services for buying and selling property; accounting services; pension products; and savings and investment products. The company was founded in 1833 and is based in Hønefoss, Norway.
Earnings Per Share
As for profitability, SPBK1 RINGERIKE has a trailing twelve months EPS of kr27.14.
PE Ratio
SPBK1 RINGERIKE has a trailing twelve months price to earnings ratio of 11.42. Meaning, the purchaser of the share is investing kr11.42 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.56%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 28.9% and 49.2%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.8%, now sitting on 973.3M for the twelve trailing months.
Sales Growth
SPBK1 RINGERIKE’s sales growth is 16.5% for the ongoing quarter and 21.7% for the next.
More news about SPBK1 RINGERIKE.
4. REACH SUBSEA (REACH.OL)
19.4% sales growth and 24.57% return on equity
Reach Subsea ASA provides subsea services in Norway and internationally. It operates in two segments, Oil & Gas and Renewable/Other. The company offers inspection, maintenance, and repair services, such as structural inspections, WROV operation, SCM changeout, scale squeeze operations, water injection, ready for operation, subsea equipment maintenance, repair, commissioning, and boulder clearance; and construction support services, including seabed intervention, boulder clearance, touchdown monitoring, and pre-lay and post- lay survey, as well as vessel, remotely operated vehicles, personnel, survey, and on demand engineering. It also provides asset integrity/pipeline inspection, and engineering and project management services; reach remote services comprising survey, inspection, and IMR and seabed intervention; seabed survey services consisting of site surveys and geohazard investigation, pipeline inspection, seabed mapping, UXO, general, and route surveys; offshore cable; marine construction; and rig and mooring services. In addition, the company offers geophysical monitoring services, which include 4D gravity, seafloor subsidence monitoring, depth watch for seismic nodes, injection integrity monitoring, well drilling, and real time seismic monitoring services; and environmental monitoring services that comprise earthquake monitoring and prediction, C02 storage, and geothermal energy exploitation. It serves oil and gas, renewables, and utilities sectors. The company was formerly known as Transit Invest ASA and changed its name to Reach Subsea ASA in December 2012. Reach Subsea ASA was incorporated in 1909 and is headquartered in Haugesund, Norway.
Earnings Per Share
As for profitability, REACH SUBSEA has a trailing twelve months EPS of kr0.67.
PE Ratio
REACH SUBSEA has a trailing twelve months price to earnings ratio of 6.85. Meaning, the purchaser of the share is investing kr6.85 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.57%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 1, 2023, the estimated forward annual dividend rate is 0.18 and the estimated forward annual dividend yield is 3.96%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 86.7%, now sitting on 1.56B for the twelve trailing months.
Sales Growth
REACH SUBSEA’s sales growth for the next quarter is 19.4%.
Moving Average
REACH SUBSEA’s value is way above its 50-day moving average of kr4.16 and above its 200-day moving average of kr4.20.
More news about REACH SUBSEA.
5. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.21.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.48. Meaning, the purchaser of the share is investing kr32.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr39.30 at 22:20 EST, below its 52-week high of kr43.60 and way higher than its 52-week low of kr29.80.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 454.46M for the twelve trailing months.
More news about NAVAMEDIC.
6. ABN AMRO BANK N.V. (ABN.AS)
17.2% sales growth and 10.93% return on equity
ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ABN AMRO BANK N.V. has a trailing twelve months EPS of €2.71.
PE Ratio
ABN AMRO BANK N.V. has a trailing twelve months price to earnings ratio of 4.84. Meaning, the purchaser of the share is investing €4.84 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.93%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 8.41B for the twelve trailing months.
More news about ABN AMRO BANK N.V..
7. ORKLA (ORK.OL)
9.4% sales growth and 13.02% return on equity
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr5.32.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 15.15. Meaning, the purchaser of the share is investing kr15.15 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.02%.
Volume
Today’s last reported volume for ORKLA is 202760 which is 75.34% below its average volume of 822557.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 14, 2023, the estimated forward annual dividend rate is 3 and the estimated forward annual dividend yield is 3.6%.
Moving Average
ORKLA’s worth is below its 50-day moving average of kr80.58 and higher than its 200-day moving average of kr76.11.
More news about ORKLA.
8. MEDISTIM (MEDI.OL)
5.8% sales growth and 34.9% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.33.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 33.49. Meaning, the purchaser of the share is investing kr33.49 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.9%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 11.9% and a drop 6.2% for the next.
Moving Average
MEDISTIM’s value is way under its 50-day moving average of kr245.96 and way below its 200-day moving average of kr249.62.
Sales Growth
MEDISTIM’s sales growth is 17.6% for the ongoing quarter and 5.8% for the next.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr212.00 at 22:20 EST, way below its 52-week high of kr312.50 and way higher than its 52-week low of kr184.80.
More news about MEDISTIM.
